Cocrystal Pharma, Inc.COCPNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank40
3Y CAGR-23.8%
5Y CAGR-1.9%
Year-over-Year Change
Research and development spending
3Y CAGR
-23.8%/yr
vs -32.2%/yr prior
5Y CAGR
-1.9%/yr
Recent deceleration
Acceleration
+8.3pp
Accelerating
Percentile
P40
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $5.47M | -56.3% |
| 2024 | $12.54M | -17.4% |
| 2023 | $15.17M | +22.4% |
| 2022 | $12.39M | +40.9% |
| 2021 | $8.79M | +45.7% |
| 2020 | $6.03M | +50.7% |
| 2019 | $4.00M | -93.2% |
| 2018 | $58.57M | +906.0% |
| 2017 | $5.82M | -94.3% |
| 2016 | $101.68M | - |